CINXE.COM
Future potential therapies for People with MS - MS Nurse PRO
<!DOCTYPE html> <html lang="en"> <head> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta name="csrf-token" content="SMZXCBUNginQzv01J6ZDoq4rHScD3hEwfJO9FlDG"> <meta name="msapplication-TileColor" content="#ffffff"> <meta name="msapplication-TileImage" content="https://msnursepro.org/ip/144/storage/images/favicon.png"> <meta name="theme-color" content="#ffffff"> <meta name="title" content="Future potential therapies for People with MS"> <meta property="og:type" content="article"> <meta property="og:site_name" content="MS Nurse PRO"> <meta property="og:url" content="https://msnursepro.org/blog/future-potential-therapies-for-people-with-ms"> <meta property="og:title" content="Future potential therapies for People with MS"> <meta property="og:image:alt" content="Future potential therapies for People with MS"> <meta name="robots" content="index, follow"> <link rel="canonical" href="https://msnursepro.org/blog/future-potential-therapies-for-people-with-ms"> <link rel="alternate" href="https://msnursepro.org/blog/future-potential-therapies-for-people-with-ms" hreflang="x-default"> <link rel="alternate" href="https://msnursepro.org/blog/future-potential-therapies-for-people-with-ms" hreflang="en"> <link rel="alternate" href="https://msnursepro.org/nl/blog/toekomstige-potentiele-therapieen-voor-mensen-met-ms" hreflang="nl"> <link rel="alternate" href="https://msnursepro.org/fr/blog/traitements-potentiels-pour-les-personnes-atteintes-de-sp" hreflang="fr"> <link rel="alternate" href="https://msnursepro.org/de/blog/zukunftige-therapiemoglichkeiten-fur-menschen-mit-ms" hreflang="de"> <link rel="alternate" href="https://msnursepro.org/el/blog/mellontikes-pithanes-therapies-ghia-atoma-me-sklirinsi-kata-plakas" hreflang="el"> <link rel="alternate" href="https://msnursepro.org/no/blog/fremtidige-potensielle-behandlinger-for-personer-med-ms" hreflang="no"> <link rel="alternate" href="https://msnursepro.org/pl/blog/przyszle-potencjalne-terapie-dla-osob-ze-stwardnieniem-rozsianym" hreflang="pl"> <link rel="alternate" href="https://msnursepro.org/pt/blog/futuras-terapias-potenciais-para-pessoas-com-em" hreflang="pt"> <link rel="alternate" href="https://msnursepro.org/ro/blog/terapii-potentiale-viitoare-pentru-persoanele-cu-sm" hreflang="ro"> <link rel="alternate" href="https://msnursepro.org/es/blog/futuras-terapias-potenciales-para-las-personas-con-em" hreflang="es"> <link rel="alternate" href="https://msnursepro.org/it/blog/potenziali-terapie-future-per-le-persone-con-sm" hreflang="it"> <link rel="alternate" href="https://msnursepro.org/cs/blog/budouci-potencialni-terapie-pro-lidi-s-rs" hreflang="cs"> <link rel="alternate" href="https://msnursepro.org/hu/blog/jovobeli-lehetseges-terapiak-sm-betegek-szamara" hreflang="hu"> <link rel="apple-touch-icon" sizes="57x57" href="https://msnursepro.org/ip/57/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="60x60" href="https://msnursepro.org/ip/60/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="72x72" href="https://msnursepro.org/ip/72/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="76x76" href="https://msnursepro.org/ip/76/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="114x114" href="https://msnursepro.org/ip/114/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="120x120" href="https://msnursepro.org/ip/120/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="144x144" href="https://msnursepro.org/ip/144/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="152x152" href="https://msnursepro.org/ip/152/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="apple-touch-icon" sizes="180x180" href="https://msnursepro.org/ip/180/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="icon" type="image/png" sizes="192x192" href="https://msnursepro.org/ip/192/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="https://msnursepro.org/ip/32/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="icon" type="image/png" sizes="96x96" href="https://msnursepro.org/ip/96/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="icon" type="image/png" sizes="16x16" href="https://msnursepro.org/ip/16/storage/logos/956-ms-nurse-pro-icon.png"> <link rel="stylesheet" href="/vendor/globistack/assets/css/website.min.css?id=9b1157c5194dbf36cdcd418217bac8782087b63ebd717ff59b4aea0e311fc368"> <link rel="stylesheet" href="/vendor/globistack/assets/css/video-js.min.css?id=9b1157c5194dbf36cdcd418217bac8782087b63ebd717ff59b4aea0e311fc368"> <link rel="stylesheet" href="/vendor/globistack/themes/css/base.min.css?id=9b1157c5194dbf36cdcd418217bac8782087b63ebd717ff59b4aea0e311fc368"> <link rel="stylesheet" href="/vendor/globistack/assets/css/lightbox.min.css?id=9b1157c5194dbf36cdcd418217bac8782087b63ebd717ff59b4aea0e311fc368"> <link rel="stylesheet" href="/storage/themes/website-b5_cekz49y/website-b5_cekz49y.min.css?id="> <style> .s-zdio2 { margin-bottom:5px; margin-top:5px; } /* social link background */ .s-zdio2 .bg { padding: 5px; width: 50px; height: 50px; display: inline-flex; background-color: #787878; align-items: center; justify-content: center; border-radius: 90px 90px 90px 90px; margin-right: 10px; } .s-zdio2 .bg:hover, .s-zdio2 .bg:focus { background-color: #5b5b5b; } /* icon size */ .s-zdio2 .fa { font-size: 27px; } /* icon color */ .s-zdio2 a { color: #FFFFFF !important; text-decoration: none !important; } /* icons color hover */ .s-zdio2 a:hover, .s-zdio2 a:focus { color: #FFFFFF !important; text-decoration: none !important; } </style><style> /* full style from LG */ @media (min-width:992px) {.main-7859 { display: inline-flex !important; flex-direction: row !important; flex-wrap: wrap !important; align-items: center !important; justify-content: flex-start !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; } } /* mobile style under LG */ @media (max-width:991px) {.main-7859 { display: flex !important; flex-direction: column !important; flex-wrap: wrap !important; justify-content: flex-start !important; margin-right: 10px !important; } } a.main-7859-item { text-decoration: none !important; text-transform: uppercase !important; color: #304a99 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 10px !important; padding-left: 10px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 16px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } .main-7859-item { text-decoration: none !important; text-transform: uppercase !important; color: #304a99 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 10px !important; padding-left: 10px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 16px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } a.main-7859-item:hover, a.main-7859-item:focus, a.main-7859-item:active, a.main-7859-item.active { color: #30b6b2 !important; font-weight: 500 !important; background-color: #ffffff !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; text-decoration: none !important; } .main-7859.show { left: 0 !important; transition-timing-function: ease-in !important; transition: left 300ms !important; } /* full style from LG */ @media (min-width:992px) {. { display: inline-flex !important; flex-direction: row !important; flex-wrap: wrap !important; align-items: center !important; justify-content: flex-start !important; margin-right: 10px !important; margin-left: 10px !important; margin-top: 0px !important; margin-bottom: 0px !important; } } /* mobile style under LG */ @media (max-width:991px) {. { display: flex !important; flex-direction: column !important; flex-wrap: wrap !important; justify-content: flex-start !important; margin-right: 10px !important; } } a.-item { text-decoration: none !important; color: #304a99 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 0px !important; padding-left: 0px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 16px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } .-item { text-decoration: none !important; color: #304a99 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 0px !important; padding-left: 0px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 16px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } a.-item:hover, a.-item:focus, a.-item:active, a.-item.active { color: #30b6b2 !important; font-weight: 500 !important; background-color: #ffffff !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; text-decoration: none !important; } ..show { left: 0 !important; transition-timing-function: ease-in !important; transition: left 300ms !important; } /* full style from LG */ @media (min-width:992px) {.top72751 { display: inline-flex !important; flex-direction: row !important; flex-wrap: wrap !important; align-items: center !important; justify-content: flex-end !important; margin-right: 0px !important; margin-left: 0px !important; margin-top: 0px !important; margin-bottom: 0px !important; } } /* mobile style under LG */ @media (max-width:991px) {.top72751 { display: flex !important; flex-direction: column !important; flex-wrap: wrap !important; justify-content: flex-start !important; margin-right: 10px !important; } } a.top72751-item { text-decoration: none !important; text-transform: uppercase !important; color: #2d4690 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 7px !important; margin-left: 7px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 0px !important; padding-left: 0px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 13px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } .top72751-item { text-decoration: none !important; text-transform: uppercase !important; color: #2d4690 !important; font-weight: 500 !important; background-color: #ffffff !important; margin-right: 7px !important; margin-left: 7px !important; margin-top: 0px !important; margin-bottom: 0px !important; padding-right: 0px !important; padding-left: 0px !important; padding-top: 5px !important; padding-bottom: 5px !important; font-size: 13px !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; } a.top72751-item:hover, a.top72751-item:focus, a.top72751-item:active, a.top72751-item.active { color: #31b6b2 !important; font-weight: 500 !important; background-color: #ffffff !important; border-bottom: 0px solid #ffffff !important; border-top: 0px solid #ffffff !important; border-left: 0px solid #ffffff !important; border-right: 0px solid #ffffff !important; text-decoration: none !important; } .top72751.show { left: 0 !important; transition-timing-function: ease-in !important; transition: left 300ms !important; } </style> <style> </style> <title>Future potential therapies for People with MS - MS Nurse PRO</title> </head> <body> <header> <div class="container mt-3"> <div class="row"> <div class="col-auto mb-3"> <div style="width:200px"> <a href="https://msnursepro.org"><img alt="ms nurse pro logo" src="https://msnursepro.org/ip/150/storage/images/msnp-logo.png"/></a> </div> </div> <div class="col d-flex justify-content-end align-items-center"> <div id="mainMenu" class="d-flex flex-column justify-content-end"> <div class="top72751"> <a alt="about us" class="top72751-item " href="https://msnursepro.org/about"> about us </a> <a alt="contact us" class="top72751-item " href="https://msnursepro.org/contact"> contact us </a> <a class="btn btn-sm btn-secondary" href="https://msnursepro.org/login"> <svg xmlns="http://www.w3.org/2000/svg" width="20" preserveAspectRatio viewBox="0 0 24 24"><path fill="currentColor" d="M11 7L9.6 8.4l2.6 2.6H2v2h10.2l-2.6 2.6L11 17l5-5l-5-5m9 12h-8v2h8c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2h-8v2h8v14Z"/></svg><span class="d-inline ms-2 ml-2"> Sign in </span> </a> <div class="dropdown mt-lg-0"> <a class="top72751-item" type="button" id="dropdownMenuButton" data-bs-toggle="dropdown" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> <div> <svg xmlns="http://www.w3.org/2000/svg" width="20" preserveAspectRatio viewBox="0 0 512 512"><path fill="currentColor" d="M320 24H16v304h176v168h304V192H320ZM148.305 96L98.093 239.3H132l8.166-23.3H192v80H48V56h240v136h-66.668L187.7 96Zm36.317 88h-33.244L168 136.562ZM464 224v240H224V224Z"/><path fill="currentColor" d="M317.432 368.48a136.761 136.761 0 0 0 10.089 14.12q-17.4 9.384-39.521 9.4v32c24.141 0 45.71-6.408 64-18.824C370.29 417.592 391.859 424 416 424v-32q-22.075 0-39.52-9.407a136.574 136.574 0 0 0 10.088-14.113A166.212 166.212 0 0 0 406.662 320H424v-32h-56v-24h-32v24h-56v32h17.338a166.212 166.212 0 0 0 20.094 48.48ZM373.53 320a133.013 133.013 0 0 1-14.1 31.52a104.39 104.39 0 0 1-7.43 10.448a103.546 103.546 0 0 1-6.93-9.651A132.384 132.384 0 0 1 330.466 320Z"/></svg> English </div> </a> <div id="lanauage" class="dropdown-menu dropdown-menu-right " aria-labelledby="dropdownMenuButton"> <a rel="noopener" class="dropdown-item active" href="https://msnursepro.org/blog/future-potential-therapies-for-people-with-ms" data-lang="en"> English </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/nl/blog/toekomstige-potentiele-therapieen-voor-mensen-met-ms" data-lang="nl"> Nederlands </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/fr/blog/traitements-potentiels-pour-les-personnes-atteintes-de-sp" data-lang="fr"> Fran莽ais </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/de/blog/zukunftige-therapiemoglichkeiten-fur-menschen-mit-ms" data-lang="de"> Deutsch </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/el/blog/mellontikes-pithanes-therapies-ghia-atoma-me-sklirinsi-kata-plakas" data-lang="el"> E位位畏谓喂魏维 </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/no/blog/fremtidige-potensielle-behandlinger-for-personer-med-ms" data-lang="no"> Norsk </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/pl/blog/przyszle-potencjalne-terapie-dla-osob-ze-stwardnieniem-rozsianym" data-lang="pl"> Polski </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/pt/blog/futuras-terapias-potenciais-para-pessoas-com-em" data-lang="pt"> Portugu锚s </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/ro/blog/terapii-potentiale-viitoare-pentru-persoanele-cu-sm" data-lang="ro"> Rom芒n膬 </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/es/blog/futuras-terapias-potenciales-para-las-personas-con-em" data-lang="es"> Espa帽ol </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/it/blog/potenziali-terapie-future-per-le-persone-con-sm" data-lang="it"> Italiano </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/cs/blog/budouci-potencialni-terapie-pro-lidi-s-rs" data-lang="cs"> 膷e拧tina </a> <a rel="noopener" class="dropdown-item " href="https://msnursepro.org/hu/blog/jovobeli-lehetseges-terapiak-sm-betegek-szamara" data-lang="hu"> Magyar </a> </div> </div> </div> <div class="mb-3 mb-xl-0"> </div> <div class="main-7859"> <a alt="Home" class="main-7859-item " href="https://msnursepro.org"> Home </a> <a alt="E-Learning" class="main-7859-item " href="https://msnursepro.org/courses"> E-Learning </a> <a alt="Hybrid learning" class="main-7859-item " href="https://msnursepro.org/hybrid-education"> Hybrid learning </a> <a alt="Webinars" class="main-7859-item " href="https://msnursepro.org/webinars"> Webinars </a> <a alt="Accreditation" class="main-7859-item " href="https://msnursepro.org/accreditations"> Accreditation </a> <a alt="Blog" class="main-7859-item " href="https://msnursepro.org/blog"> Blog </a> <a alt="MSPEDIA" class="main-7859-item " href="https://msnursepro.org/mspedia"> MSPEDIA </a> <a alt="FAQ" class="main-7859-item " href="https://msnursepro.org/faq"> FAQ </a> </div> </div> <button onclick="mobileMenu()" type="button" class="btn btn-sm btn-secondary menu-toggle"> <svg xmlns="http://www.w3.org/2000/svg" width="20" preserveAspectRatio fill="currentColor" viewBox="0 0 24 24"><path d="M3,6H21V8H3V6M3,11H21V13H3V11M3,16H21V18H3V16Z" /></svg> <span class="d-md-inline-block d-none ml-1">MENU</span> </button> </div> </div> </div> </header> <div class="container"></div> <section style="max-width:1000px; margin-left:auto; margin-right:auto;"> <div class="container mt-5"> <div class="row"> <div class="col-12"> <a class="btn btn-block text-left text-start" href="https://msnursepro.org/blog"><svg xmlns="http://www.w3.org/2000/svg" width="20" preserveAspectRatio viewBox="0 0 15 15"><path fill="currentColor" d="m2.707 8l3.147 3.146l-.708.707L.793 7.5l4.353-4.354l.708.708L2.707 7H14v1H2.707Z" clip-rule="evenodd"/></svg> BLOG</a> </div> <div class="col-12 mt-3 mb-3"> <img src="https://msnursepro.org/storage/articles/238-future-potential-therapies-for-people-with-ms-img.jpg" alt="Future potential therapies for People with MS" srcset="https://msnursepro.org/ip/1000/storage/articles/238-future-potential-therapies-for-people-with-ms-img.jpg 1000w, https://msnursepro.org/ip/2000/storage/articles/238-future-potential-therapies-for-people-with-ms-img.jpg 2000w" data-auto-dimensions="true"> </div> <div class="col-12"> <h1>Future potential therapies for People with MS</h1> <div class="row small"> <div class="col-md-4"> <div class="d-flex align-items-center"> <svg xmlns="http://www.w3.org/2000/svg" width="15" preserveAspectRatio fill="currentColor" viewBox="0 0 24 24"><path d="M19 3H18V1H16V3H8V1H6V3H5C3.89 3 3 3.9 3 5V19C3 20.11 3.9 21 5 21H19C20.11 21 21 20.11 21 19V5C21 3.9 20.11 3 19 3M19 19H5V9H19V19M19 7H5V5H19V7Z" /></svg> <span class="ms-1">08/11/2024</span> </div> </div> <div class="col-md-4"> <div class="d-flex align-items-center justify-content-center"> <svg xmlns="http://www.w3.org/2000/svg" width="15" preserveAspectRatio fill="currentColor" viewBox="0 0 24 24"><path d="M12,4A4,4 0 0,1 16,8A4,4 0 0,1 12,12A4,4 0 0,1 8,8A4,4 0 0,1 12,4M12,6A2,2 0 0,0 10,8A2,2 0 0,0 12,10A2,2 0 0,0 14,8A2,2 0 0,0 12,6M12,13C14.67,13 20,14.33 20,17V20H4V17C4,14.33 9.33,13 12,13M12,14.9C9.03,14.9 5.9,16.36 5.9,17V18.1H18.1V17C18.1,16.36 14.97,14.9 12,14.9Z" /></svg><span class="ms-1">Elena Kelly</span> </div> </div> <div class="col-md-4"> <div class="d-flex justify-content-end"> <div class="d-flex align-items-center"><svg xmlns="http://www.w3.org/2000/svg" width="15" preserveAspectRatio fill="currentColor" viewBox="0 0 24 24"><path d="M12,9A3,3 0 0,1 15,12A3,3 0 0,1 12,15A3,3 0 0,1 9,12A3,3 0 0,1 12,9M12,4.5C17,4.5 21.27,7.61 23,12C21.27,16.39 17,19.5 12,19.5C7,19.5 2.73,16.39 1,12C2.73,7.61 7,4.5 12,4.5M3.18,12C4.83,15.36 8.24,17.5 12,17.5C15.76,17.5 19.17,15.36 20.82,12C19.17,8.64 15.76,6.5 12,6.5C8.24,6.5 4.83,8.64 3.18,12Z" /></svg> <span class="ms-1">234</span></div> </div> </div> </div> </div> </div> </div> <div class="mt-3"> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ed866-31aa-44f4-a90f-7d0f3d01453f"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><p>As nurses, we receive questions from our patients regarding the possibility of future therapies for MS.</p><p>In this blogpost, we highlight developments regarding hematopoietic stem cell transplantation and two potential future therapies that were discussed at the recent (September 2024)<span style="text-decoration: underline;" data-mce-style="text-decoration: underline;"> <a href="https://ectrims.eu/ectrims2024-programme/" target="_blank" rel="noopener" data-mce-href="https://ectrims.eu/ectrims2024-programme/">Congress of the European Committee for the Treatment and Research in Multiple Sclerosis</a></span> society, the world鈥檚 largest gathering of MS healthcare professionals.</p></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6edcd9-2e5c-4aeb-884e-a90735801055"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h3>Hematopoietic stem cell transplantation as an immune reconstitution therapy</h3><p>Despite still being experimental, experience with hematopoietic stem cell transplant (HSCT) is increasing and this was highlighted by two representative real-world studies presented at the congress.<sup>1,2聽</sup></p><p>An uncontrolled real-world study of 363 patients with MS in the UK (38% with progressive MS) found that, at 2 years and 5 years after undergoing HSCT, 94.6% and 88.6% of patients were in relapse-free survival (RFS) respectively.<sup>1</sup> In addition, magnetic resonance imaging (MRI)-free activity survival (MFS) was 88.2% and 78.8% at 2 and 5 years, respectively. On the Expanded Disability Status Scale (EDSS), the cumulative incidence of improvement was 24.6% at 2 years and 28.6% at 5 years. There was no evidence of disease activity (NEDA) on the endpoints of symptoms, relapse, and MRI (NEDA-3) in 72% of patients at 2 years and 48.5% at 5 years. There were four deaths during the study but all occurred at an early stage of the HSCT programme when there was limited experience in the management of cytopenias and other acute complications of HSCT. The authors concluded that stem cell transplant led to a durable remission of inflammatory activity and to clinical stability.</p></div> </div> </section> <section data-block="9b89208c-a48a-47f2-8260-96428760d5d6" data-id="9d6ed850-28ec-4527-898f-2309f8b11773" class="" style="margin-top: 0px; margin-bottom: 0px; padding-top: 14px; padding-bottom: 14px; background-color: transparent;"> <div class="container" style="background-color: transparent;"> <div class="row g-5"> <div class="col-lg-6 d-flex justify-content-center"> <div style="max-width: 500px; position:relative;"> <picture> <source media="(max-width: 600px)" srcset="/ip/250/storage/835-placeholder.jpg"> <source media="(min-width: 601px)" srcset="/ip/500/storage/835-placeholder.jpg"> <img src="/ip/500/storage/835-placeholder.jpg" alt="placeholder" data-auto-dimensions="true"> </picture> </div> </div> <div class="col-lg-6"> <div data-editor="tiny-w" id="" class="" style=""><p>A real-world study in Italy looked at 97 patients with relapsing-remitting MS (RRMS) treated with HSCT who were matched with 314 patients treated with alemtuzumab and compared with propensity score overlap weighting.<sup>2</sup> After a median follow-up of 62 months in the HSCT group and 30 months in the alemtuzumab group, HSCT outperformed drug therapy on all efficacy measures. When translated into hazard ratios (HR), HSCT relative to alemtuzumab was associated with a 50% reduction in the probability of disability progression (HR, 0.50; p=0.025), a 66% reduction in probability of relapse (HR, 0.34; p<0.001), and a 62% reduction in the probability of MRI activity (HR, 0.38; p<0.001). At 5 years, 58.3% the HSCT group versus 22.3% of the alemtuzumab group maintained NEDA-3, representing >50% reduction (HR, 0.48; p<0.001). There were two treatment-related deaths; both occurred within 30 days of HSCT and, similarly to the UK study, were confined to the early experience with HSCT.</p></div> </div> </div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ed979-8bc5-436c-b34f-60d89d9ca9e7"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><p>Both studies concluded that ongoing randomised controlled trials are needed to confirm these results and to define predictors of response to HSCT.</p></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ed87c-cd96-4944-97ab-bfba304f62b5"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h3 style="text-align: center;" data-mce-style="text-align: center;">Bruton's tyrosine kinase inhibitors</h3></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ede9c-106e-4585-bd81-0c1b2123531c"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><p>Bruton tyrosine kinase (BTK) is an important intracellular signalling molecule involved in regulating the maturation, proliferation, survival and activation of B cells and myeloid cells. BTK inhibitors are an emerging class of therapeutics in MS that block the activity of BTK. Tolebrutinib is a highly selective BTK inhibitor and results from its phase 3 clinical development programme were presented at the congress.</p></div> </div> </section> <section data-block="9b891fb2-1c30-44bd-8ac8-69efc8455e10" data-id="9d6ed86e-d5ad-4853-92d8-2f3d4b523784" class="" style="margin-top: 0px; margin-bottom: 0px; padding-top: 20px; padding-bottom: 14px; background-color: transparent;"> <div class="container" style="background-color: transparent;"> <div class="row g-5 d-flex flex-column-reverse flex-lg-row"> <div class="col-lg-6"> <div data-editor="tiny-w" id="" class="" style=""><h4 style="text-align: center;" data-mce-style="text-align: center;">HERCULES</h4><p>HERCULES enrolled 1,131 adults with non-relapsing secondary-progressive MS (SPMS) randomly assigned to receive daily oral tolebrutinib (60 mg) or placebo for up to four years.<sup>3</sup> The main goal was to determine if tolebrutinib could delay disability progression. Significantly fewer people on tolebrutinib experienced a six-month confirmed disability worsening (CDW) event relative to those in the placebo group (26.9% vs. 37.2%). This amounted to a 31% lower risk of disability progression with tolebrutinib (HR 0.69; 95% CI 0.55-0.88; p=0.0026). Further analysis of secondary endpoints demonstrated that confirmed disability improvement was 10% with tolebrutinib compared to 5% with placebo (HR 1.88; 95% CI 1.10 to 3.21; nominal p=0.021).</p></div> </div> <div class="col-lg-6 d-flex justify-content-center"> <div style="max-width: 500px; position:relative;"> <picture> <source media="(max-width: 600px)" srcset="/ip/250/storage/797-placeholder.jpg"> <source media="(min-width: 601px)" srcset="/ip/500/storage/797-placeholder.jpg"> <img src="/ip/500/storage/797-placeholder.jpg" alt="placeholder" data-auto-dimensions="true"> </picture> </div> </div> </div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ee1f5-fc0d-4d2a-9ef0-e38b8360bfc5"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h4 style="text-align: center;" data-mce-style="text-align: center;">GEMINI 1 and GEMINI 2</h4></div> </div> </section> <section data-block="9b7fa1d4-fe51-4289-b2d6-501978a42fcb" data-id="9d6ed871-0be7-48e9-a29c-a4d3e1820365"> <div class="container"> <div class="row gy-4"> <div class="col-lg-6"> <div class="w-100 p-0 p-lg-4" data-editor="tiny-w" id="" style=""><p>GEMINI 1 and GEMINI 2 collectively enrolled more than 1,800 people with relapsing forms of MS, including PRMS and active SPMS and randomly assigned them to receive tolebrutinib or teriflunomide daily for up to three years.<sup>4</sup> Both studies did not meet the primary endpoint of statistically significant improvement in annualised relapse rates (ARR) compared to teriflunomide. However, in the key secondary endpoint, tolebrutinib delayed the time to onset of 6-month CDW by 29% compared to teriflunomide (9.9% vs 13.2%, HR 0.71; 95% CI: 0.53-0.95; nominal p=0.023).聽</p></div> </div> <div class="col-lg-6"> <div class="w-100 p-0 p-lg-4" data-editor="tiny-w" id="" style=""><p>In both studies, tolebrutinib was generally well tolerated, although a small percentage of patients in both trials experienced significant increases in liver enzymes, and a single patient in HERCULES required a liver transplant and later died from complications of that transplant. These elevations in liver enzymes all occurred in the first three months of dosing.<br>Results from these studies suggest that tolebrutinib can target the underlying, smoldering inflammation process that drives disease progression. Sanofi plans to begin submitting applications for tolebrutinib鈥檚 approval in the second half of 2025.</p></div> </div> </div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ee4ed-30a2-44ab-b529-270e5d309cab"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h3 style="text-align: center;" data-mce-style="text-align: center;">Chimeric antigen receptor T-cell therapies</h3></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ee20b-0e92-453e-8f48-82f426db2009"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><p>Chimeric antigen receptor (CAR) T-cell therapies have begun to demonstrate curative potential use in autoimmune disease. CAR T-cell therapy involves modifying a patient鈥檚 T cells to recognise and remove B cells in the patient鈥檚 body.<sup>5聽</sup><br><br></p></div> </div> </section> <section data-block="9b7fa1d4-fe51-4289-b2d6-501978a42fcb" data-id="9d6ed882-b931-4d42-a465-6853651388e4"> <div class="container"> <div class="row gy-4"> <div class="col-lg-6"> <div class="w-100 p-0 p-lg-4" data-editor="tiny-w" id="" style=""><p>KYV-101 is an autologous fully human anti-CD19 CAR T-cell therapy, specifically targeting CD19, a protein expressed on the surface of B-cells, which is involved in various types of autoimmune diseases. The therapy aims to directly deplete B-cells, potentially resetting disease-contributing B-cells.<sup>5</sup></p></div> </div> <div class="col-lg-6"> <div class="w-100 p-0 p-lg-4" data-editor="tiny-w" id="" style=""><p>KYV-101 is currently being evaluated in a range of B-cell-driven autoimmune diseases. KYSA-7 is the first phase 2, open-label, randomised, multicentre study of KYV-101 in treatment refractory primary and secondary progressive MS and the study design was outlined in a poster at the congress.<sup>6</sup></p></div> </div> </div> </div> </section> <section data-block="9b89208c-a48a-47f2-8260-96428760d5d6" data-id="9d6ee3db-f335-4e91-93ca-de9ee01f9f93" class="" style="margin-top: 0px; margin-bottom: 0px; padding-top: 14px; padding-bottom: 14px; background-color: transparent;"> <div class="container" style="background-color: transparent;"> <div class="row g-5"> <div class="col-lg-6 d-flex justify-content-center"> <div style="max-width: 500px; position:relative;"> <picture> <source media="(max-width: 600px)" srcset="/ip/250/storage/171-placeholder.jpg"> <source media="(min-width: 601px)" srcset="/ip/500/storage/171-placeholder.jpg"> <img src="/ip/500/storage/171-placeholder.jpg" alt="placeholder" data-auto-dimensions="true"> </picture> </div> </div> <div class="col-lg-6"> <div data-editor="tiny-w" id="" class="" style=""><p><br></p><p><br></p><p>Case report experience in five patients with MS treated with KYV-101, who failed prior anti-CD20 medications, have shown a significant average reduction in oligoclonal bands in the central nervous system, a potential surrogate biomarker for reduced disease progression.7</p><p>Across 41 autoimmune disease patients treated to date with KYV-101, no severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) has been observed.</p></div> </div> </div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ee2ed-f42d-413c-8958-6b423e24b469"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><p><em>While a cure for MS remains elusive, continued progress in research and the development of new treatments offer hope for those living with this chronic and often disabling condition. Despite there being no immediate (2024/2025) new therapies on the horizon, there is hope that some of the therapies in development described above will have the potential to improve patient care in the near future. 聽</em></p></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d6ee487-5f9f-4860-8f55-1b18775e87d1"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h6>References</h6><p><br>1. Muraro P, Kazmi M, De Matteis E, et al. Real-world Effectiveness and Safety of Autologous Haematopoietic Stem Cell Transplantation in MS: the UK Experience in 363 patients treated during 2002-2023. ECTRIMS 2024:Abstract 1702/O018<br>2. Signori A, Boffa G, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation vs Alemtuzumab in Multiple Sclerosis: an Italian multicenter study. ECTRIMS 2024:Abstract 243/O019<br>3. Fox R, et al. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results from the Phase 3 HERCULES Trial. ECTRIMS 2024: late breaking abstract<br>4. Oh J, et al. Efficacy and Safety of Tolebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results from the Phase 3 GEMINI 1 and 2 Trials. ECTRIMS 2024: late breaking abstract<br>5. https://kyvernatx.com/patients/multiple-sclerosis/ Accessed October 2024<br>6. Dunn J, Friese M, Cree B, et al. Design of KYSA-7, A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment Refractory Primary and Secondary Progressive Multiple Sclerosis. ECTRIMS 2024; Poster P1594<br>7. Kyverna ECTRIMS Symposium Presentation. September 2024. Available at https://ir.kyvernatx.com/static-files/1a98460d-d29e-445d-8839-2c98dc72c31c Accessed October 2024</p></div> </div> </section> <section data-block="9b3a56a2-f645-45de-8b16-b02b939c4f93" data-id="9d7a7e19-b80a-4ed9-89fe-cca3c3691207"> <div class="container"> <div class="w-100" data-editor="tiny-w" id="" style=""><h6>About our translations</h6><p>All Blogposts, e-learning Courses, e-Newsletters, e-Newsflashes and the website content of MS Nurse PRO is originally created in English (UK).聽<br>Our Educational Read Blogposts and our e-learning courses are reviewed by our scientific committee on accuracy and objectiveness.聽<br>Next, the content is auto-translated by Microsoft Translator and made available on our platform.聽<br>The translated content is not language reviewed with the exception of our e-learning Course content.<br>MS Nurse PRO has put a process in place to have our e-learning Courses language reviewed by native speaking experts (nurses or neurologists).聽<br>We make all translated e-learning Courses available immediately and next, the language review process is started. This review process can take several months.聽</p></div> </div> </section> </div> <div class="mt-3 p-3 mb-3"> <a href="https://msnursepro.org/tags/educational-reads"><span class="badge bg-info">Educational reads</span></a> </div> </section> <footer class="mt-5"> <div class="footer-grad gradient-bg"></div> <div class="footer-inner innerpage row"> <div class="col-lg-3 col-md-6 mt-3"> <div class="gs-logo"> <a href="https://msnursepro.org"><img alt="ms nurse pro logo" src="https://msnursepro.org/ip/150/storage/images/msnp-logo.png"/></a> </div> </div> <div class="col-lg-3 col-md-6 mt-3"> <div class="h5 text-capitalize">Resources</div> <div class="d-flex flex-column"> <a alt="Blog" rel="noopener" class="-item " href="https://msnursepro.org/blog" > Blog </a> <a alt="Learn" rel="noopener" class="-item " href="https://msnursepro.org/courses" > Learn </a> <a alt="FAQ" rel="noopener" class="-item " href="https://msnursepro.org/faq" > FAQ </a> <a alt="MSPEDIA" rel="noopener" class="-item " href="https://msnursepro.org/mspedia" > MSPEDIA </a> <a alt="Endorsements" rel="noopener" class="-item " href="https://msnursepro.org/endorsements" > Endorsements </a> <a alt="Accreditations" rel="noopener" class="-item " href="https://msnursepro.org/accreditations" > Accreditations </a> <a alt="Supporters" rel="noopener" class="-item " href="https://msnursepro.org/supporters" > Supporters </a> <a alt="Promotional Materials" rel="noopener" class="-item " href="https://msnursepro.org/promotional-materials" > Promotional Materials </a> </div> </div> <div class="col-lg-3 col-md-6 mt-3"> <div class="h5 text-capitalize">Legal</div> <div class="d-flex flex-column"> <a alt="Log-in" rel="noopener" class="-item " href="https://msnursepro.org/login" > Log-in </a> <a alt="Register" rel="noopener" class="-item " href="https://msnursepro.org/register" > Register </a> <a alt="Privacy" rel="noopener" class="-item " href="https://msnursepro.org/privacy" > Privacy </a> <a alt="Terms" rel="noopener" class="-item " href="https://msnursepro.org/terms" > Terms </a> </div> </div> <div class="col-lg-3 col-md-6 mt-3"> <div id="subscribe" class="h5">Subscribe to newsletter</div> <div class="text-center mb-4"> <div class="mt-2 mb-2"> <a href="https://msnursepro.org/mailing/social/optin/google" class="google-login-btn"> <img src="/images/google-icon.svg" width="20" height="20">Subscribe with Google</a> </div> <div class="mt-2 mb-2"> <a rel="noopener" href="https://msnursepro.org/mailing/social/optin/microsoft" class="microsoft-btn"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" preserveAspectRatio="" fill="currentColor"><path d="M0 32h214.6v214.6H0V32zm233.4 0H448v214.6H233.4V32zM0 265.4h214.6V480H0V265.4zm233.4 0H448V480H233.4V265.4z"></path></svg> <div>Subscribe with Microsoft</div> </a> </div> </div> </div> </div> </footer> <section class="mt-3 mb-5"> <div class="container"> <div class="row"> <div class="col-md-6 d-flex d-md-flex justify-content-center justify-content-md-start"> <div style="color: #cdcdcd; font-size: 0.8rem;"><span>© Copyright</span> <span>EMSP VZW</span> </div> </div> <div class="col-md-6 d-flex d-md-flex justify-content-center justify-content-md-end mt-2 mt-lg-0"> <div style="color: #cdcdcd; font-size: 0.8rem;"> <a target="__blank" rel="noopener" alt="Affordable All-in One Business Software" href="https://globistack.com" style="color: #cdcdcd !important; text-decoration: none !important; width:20px;"> <svg style="width:20px" version="1.1" id="a" xmlns="http://www.w3.org/2000/svg" fill="currentColor" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 465 458.8" > <g id="b"> <path class="st0" d="M154,12.6v77.1C77.3,132.9,50.5,229.2,94.2,304.9c6.4,11.2,14.3,21.6,23.3,30.9L65,387.7 C23.2,345-0.1,288,0,228.6C0,129.1,64.2,44.4,154,12.6"/> <path class="st1" d="M465,229.4c0,126.7-104.1,229.4-232.5,229.4c-20.9,0-41.7-2.7-62-8.3c-5.6-1.5-11.2-3.2-16.6-5.1 c-28.4-10.1-54.7-25.6-77.2-45.6l52.7-52c7.6,6.4,15.8,12.1,24.5,17c24.1,13.5,51.4,20.7,79.1,20.7c47.8,0.1,93-21,123.3-57.4h0.1 v-0.2c0.6-0.8,1.4-1.6,2-2.5l-182.8-96.8L358.6,130C314,74.2,236.9,54.7,170.6,82.5V8.3c20.2-5.5,41-8.3,61.9-8.3 C361,0,465,102.7,465,229.4 M358.5,182h43v42.5h-43V182z M358.5,232.9h43v42.5h-43V232.9L358.5,232.9z M306.9,182h43v42.5h-43V182z M306.9,232.9h43v42.5h-43V232.9L306.9,232.9z"/> </g> </svg> </a> </div> </div> </div> </div> </section> <script src="/vendor/globistack/assets/js/website.min.js?id=9b1157c5194dbf36cdcd418217bac8782087b63ebd717ff59b4aea0e311fc368"></script> <script src="/vendor/globistack/assets/js/video-js.min.js"></script> <script src="/storage/themes/website-b5_cekz49y/website-b5_cekz49y.min.js?id="></script> <div class="bg-light bottom-0 end-0 fixed-bottom p-4 start-0 w-100"> <form method="POST" action="https://msnursepro.org/cookie-preferences/accept-all" accept-charset="UTF-8"><input type="hidden" name="_token" value="SMZXCBUNginQzv01J6ZDoq4rHScD3hEwfJO9FlDG"> <div class="gs-cookie-wall-title"> <b>Cookie notice</b> </div> <div class="gs-cookie-wall-text"> We use cookies to enhance your website experience, to analyze site usage and assist in our marketing efforts. You can accept to authorize all or configure your preferences. </div> <div class="mt-2"> <button type="submit" class="btn btn-sm btn-success me-2 mr-2">Accept</button> <button data-bs-toggle="modal" data-bs-target="#cookieConfigModal" type="button" class="btn btn-secondary btn-sm me-2 mr-2" data-gs-cookie-preference-btn="configure">Configure</button> </div> </form></div> <div class="modal fade" id="cookieConfigModal" tabindex="-1" aria-labelledby="cookieConfigModalLabel" aria-hidden="true"> <div class="modal-dialog"> <div class="modal-content"> <div class="modal-header"> <h5 class="modal-title" id="cookieConfigModalLabel">Cookie settings</h5> </div> <div data-gs-cookie-preference-content="setting" class="modal-body"> <form method="POST" action="https://msnursepro.org/cookie-preferences/accept-selected" accept-charset="UTF-8"><input type="hidden" name="_token" value="SMZXCBUNginQzv01J6ZDoq4rHScD3hEwfJO9FlDG"> <div class="h5 mb-3"> Select the cookies you accept. </div> <div class="gs-cookie-type mb-2"> <div class="custom-control custom-switch form-check form-switch"> <input class="custom-control-input form-check-input" type="checkbox" name="cookie_types[]" id="9945e166-5719-4dca-96a1-502349922b4e" value="9945e166-5719-4dca-96a1-502349922b4e" checked="1" disabled="1"> <label class="custom-control-label form-check-label font-weight-bold" for="9945e166-5719-4dca-96a1-502349922b4e"> essential cookies </label> <div class="gs-cookie-wall-text"> Essential cookies or strictly necessary cookies are cookies that are essential for a website to function correctly. </div> </div> </div> <div class="gs-cookie-type mb-2"> <div class="custom-control custom-switch form-check form-switch"> <input class="custom-control-input form-check-input" type="checkbox" name="cookie_types[]" id="9945e166-5bd7-4282-af5f-e6bad18cfee3" value="9945e166-5bd7-4282-af5f-e6bad18cfee3"> <label class="custom-control-label form-check-label font-weight-bold" for="9945e166-5bd7-4282-af5f-e6bad18cfee3"> preferences cookies </label> <div class="gs-cookie-wall-text"> Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language. </div> </div> </div> <div class="gs-cookie-type mb-2"> <div class="custom-control custom-switch form-check form-switch"> <input class="custom-control-input form-check-input" type="checkbox" name="cookie_types[]" id="9945e166-5f10-4fb5-a976-14f22e65fac6" value="9945e166-5f10-4fb5-a976-14f22e65fac6"> <label class="custom-control-label form-check-label font-weight-bold" for="9945e166-5f10-4fb5-a976-14f22e65fac6"> marketing cookies </label> <div class="gs-cookie-wall-text"> Marketing cookies enable a website to optimize marketing efforts, create profiles and send advertising campaigns more efficiently. </div> </div> </div> <div class="gs-cookie-type mb-2"> <div class="custom-control custom-switch form-check form-switch"> <input class="custom-control-input form-check-input" type="checkbox" name="cookie_types[]" id="9945e166-623c-4f45-9ad7-82c46cc02a9f" value="9945e166-623c-4f45-9ad7-82c46cc02a9f"> <label class="custom-control-label form-check-label font-weight-bold" for="9945e166-623c-4f45-9ad7-82c46cc02a9f"> analytics cookies </label> <div class="gs-cookie-wall-text"> Analytics cookies are cookies that track how users navigate and interact with a website. </div> </div> </div> <div class="mt-3 text-end"> <button type="submit" class="btn btn-sm btn-success me-2 mr-2">Save</button> </div> </form> </div> </div> </div> </div> <script> document.querySelectorAll('#mainMenu a').forEach((el, i) => { if(el.getAttribute('href') == window.location.href.replace(/\/$/, '')) { el.classList.add('active'); } }); </script> </body> </html>